Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 10/20 | 0.51 |
| ▸ | XDH | P47989 | 4/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21539446 | 0.80 | PNP (0.49) | PNPXDHTK1MITFTP53 | |
| SCHEMBL13395298 | 0.79 | PNP (0.33) | PNP | |
| SCHEMBL19018642 | 0.79 | KMT2A (0.35) | PNP | |
| SCHEMBL13850522 | 0.78 | PNP (0.45) | PNPXDHMITFTP53THRB | |
| SCHEMBL21126204 | 0.78 | PNP (0.48) | PNPXDHMITFTP53THRB | |
| SCHEMBL13396185 | 0.78 | PNP (0.45) | PNPXDHMITFTP53THRB | |
| SCHEMBL13851083 | 0.78 | PNP (0.58) | PNPXDH | |
| SCHEMBL21126210 | 0.77 | PNP (0.44) | PNPXDHMITFTP53THRB | |
| SCHEMBL24434585 | 0.76 | PNP (0.46) | PNPXDHTK1MITFTP53 | |
| SCHEMBL21127782 | 0.76 | PNP (0.59) | PNPXDHTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566775-B2 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-07-28 | — | — | US | claimed |
| US-20060135462-A1 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2006-06-22 | — | — | US | claimed |
| US-7063945-B2 | N8 -and c8 -linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC (US) | 2006-06-20 | — | — | US | claimed |
| US-20040171820-A1 | N8-and c8-linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC | 2004-09-02 | — | — | US | claimed |
| EP-1301523-A1 | N8 - AND C8 -LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | Roche Diagnostics GmbH (DE) | 2003-04-16 | — | — | EP | claimed |
| WO-2001072764-A1 | N?8- AND C8¿-LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | WO | claimed |
| EP-1138688-A1 | N8- and C8- linked purine bases as universal nucleosides used for oligonucleotide hybridization | Roche Diagnostics GmbH (DE) | 2001-10-04 | — | — | EP | claimed |
| EP-1138689-A1 | N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization | Roche Diagnostics GmbH (DE) | 2001-10-04 | — | — | EP | claimed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| CN-116782889-A | Enhanced formulation stability and improved lyophilization process | 生物技术欧洲股份公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4242212-A2 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-7063945-B2 | N8 -and c8 -linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040171820-A1 | N8-and c8-linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC | 2004-09-02 | — | — | US | disclosed |
| EP-1301523-A1 | N8 - AND C8 -LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | Roche Diagnostics GmbH (DE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2001072764-A1 | N?8- AND C8¿-LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | WO | disclosed |
| EP-1138688-A1 | N8- and C8- linked purine bases as universal nucleosides used for oligonucleotide hybridization | Roche Diagnostics GmbH (DE) | 2001-10-04 | — | — | EP | disclosed |
| EP-1138689-A1 | N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization | Roche Diagnostics GmbH (DE) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135462-A1 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | NUDT1, NT5C3B, NT5C2 | PNP 10/4885XDH 776/4885TK1 95/4885 |
| US-20040171820-A1 | N8-and c8-linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | NUDT1, NT5C3B, NT5C2 | PNP 9/4885XDH 802/4885TK1 113/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | PNP 174/4885XDH 1435/4885TK1 216/4885 |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | PNP 47/4885XDH 2570/4885TK1 277/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | PNP 462/4885XDH 16/4885TK1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.